Study details
Enrolling now
A Study Evaluating BFB759 in Moderate to Severe Hidradenitis Suppurativa
Bluefin Biomedicine, Inc.
NCT IDNCT07287644ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2/3
Target enrollment
210
Study length
about 1.7 years
Ages
18–75
Locations
31 sites in AZ, CA, FL +15
What this study is about
Researchers are testing whether BFB759, a biological treatment, is effective and safe compared to a placebo for people with moderate to severe hidradenitis suppurativa. The trial will last approximately 36 to 40 weeks.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Placebo for BFB759
- 2.Receive BFB759
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
Randomized & Blinded
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Endpoints
Secondary: Evaluate the safety/tolerability of BFB759, To evaluate the clinical activity of BFB759 using the Skin Pain Numerical Rating Scale (NRS)